Merck's Idvynso Gains FDA Approval as Novel Dual-Drug HIV Treatment
CompanyDrug

Merck’s Idvynso Gains FDA Approval as Novel Dual-Drug HIV Treatment

CompanyDeals

Boji Medical Sells Fluconazole Ear Drops Technology to Chengdu Pusch for $2M

CompanyDrug

Roche’s Fenebrutinib Slashes MS Relapse Rates by Over 50% in Phase III Trials

Novabio Therapeutics and OBiO Tech Strengthen Partnership to Advance Treg Cell Therapies for Neurodegenerative Diseases
CompanyDeals

Novabio Therapeutics and OBiO Tech Strengthen Partnership to Advance Treg Cell Therapies for Neurodegenerative Diseases

CompanyDrug

Gan & Lee’s Nectin-4 ADC GLR1059 Clears Regulatory Hurdle for Solid Tumor Trials

Danaher Q1 Earnings Beat Expectations as Bioprocessing Strength Offsets Cepheid Weakness
Company

Danaher Q1 Earnings Beat Expectations as Bioprocessing Strength Offsets Cepheid Weakness

CompanyDrug

Leads Biolabs Enrolls First Patient in Phase II Trial for Gastric Cancer Drug Opamtistomig

Roche's Gazyva Gains FDA Review Acceptance for Systemic Lupus Erythematosus Treatment
CompanyDrug

Roche’s Gazyva Gains FDA Review Acceptance for Systemic Lupus Erythematosus Treatment

InxMed Limited Files for Hong Kong IPO with Near-Commercial FAK Inhibitor Ifebemtinib
CompanyDeals

InxMed Limited Files for Hong Kong IPO with Near-Commercial FAK Inhibitor Ifebemtinib

Daiichi Sankyo and AstraZeneca Launch Datroway ADC in China for HR-Positive, HER2-Negative Breast Cancer
CompanyDrug

Daiichi Sankyo and AstraZeneca Launch Datroway ADC in China for HR-Positive, HER2-Negative Breast Cancer

CompanyDrug

Merck and Eisai’s LITESPARK-012 Trial Fails to Meet Primary Endpoints in Advanced Kidney Cancer

AstraZeneca's Ultomiris Shows Significant Proteinuria Reduction in Phase III IgA Nephropathy Trial
CompanyDrug

AstraZeneca’s Ultomiris Shows Significant Proteinuria Reduction in Phase III IgA Nephropathy Trial